Clinsys Supports Breast Cancer Research through Passionately Pink for the Cure Initiative
Clinsys Clinical Research, a therapeutically focused global contract research organization, announced the launch of its Passionately Pink for the Cure campaign, a company-wide breast cancer awareness and fundraising program supporting Susan G. Komen for the Cure.
Clinsys® Supports Breast Cancer Research through Passionately Pink for the Cure® Initiative
BEDMINSTER, NEW JERSEY (October 1, 2008) -
Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of its Passionately Pink for the Cure campaign, a company-wide breast cancer awareness and fundraising program supporting Susan G. Komen for the Cure®. All donations received through the year-long Clinsys Passionately Pink campaign will be matched by the company.
“For more than 15 years, Clinsys has dedicated its clinical trial expertise to finding cures for all forms of cancer,” said David E. Williams, Chief Executive Officer of Clinsys. “We are proud to take our commitment to research one step further by participating in the Passionately Pink program and sharing in the vision of Susan G. Komen—a world without breast cancer.”
Passionately Pink for the Cure is a national grassroots program in which companies, organizations, social groups and individuals select a day to wear pink, and each group member donates $5 or more to Komen for the Cure. Of the donations received through Passionately Pink for the Cure, 75 percent will go toward breast cancer research, and the remaining 25 percent will be shared with Komen affiliates to support local education, screening and treatment efforts.
“Nearly everyone knows someone who has been affected by breast cancer. Going Passionately Pink is an easy and fun way to show your support for ending the disease,” said breast cancer survivor Hala Moddelmog, president and CEO of Komen for the Cure. “Passionately Pink for the Cure participants play a critical role in helping us create a world without breast cancer—and they do it in style!”
Clinsys’ fundraising campaign will feature a week-long celebration October 20-24, 2008, with the organization’s Passionately Pink day being held Friday, October 24. During the week, Clinsys will promote breast cancer advocacy by distributing educational materials to employees and hosting a variety of awareness-oriented events.
To make a donation or for further information about the Passionately Pink campaign, please visit the Clinsys Passionately Pink Team website <
http://app.bronto.com/public/?q=ulink&fn=Link&ssid=8886&id=23pyohswq90ngtca9rlr96mm5g17f&id2=fytt7n4ojwj6w74rb2216tip9mgbx
> .
About Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc.®, is a therapeutically focused global contract research organization that provides pharmaceutical, biotechnology and medical device companies with a full range of clinical research services in support of Phase I-IV drug and device development. Clinsys has expertise in highly specialized therapeutic areas, including oncology, central nervous system, dermatology, respiratory and cardiovascular. To ensure all projects are completed successfully and efficiently, Clinsys employs its Global Program Solutions£, which integrate its Global Project Solution® (Clinsys GPS®) methodology with Therapeutically Aligned Program Strategists£ (Clinsys TPS£) team capabilities.
Clinsys is a Jubilant Organosys company headquartered in Bedminster, New Jersey, with operations in Raleigh, North Carolina; Philadelphia, Pennsylvania; and Düsseldorf, Germany. Clinsys Clinical Research, Ltd., with offices in Noida and Bangalore, India, provides extensive clinical research services for Phase I-IV drug development, and operates a clinical pharmacology unit performing bioavailability and bioequivalence studies as well as bioanalytical sample analysis, clinical laboratory and pathology services. Clinsys ALTERNA£ (clinsysalterna.com <
http://app.bronto.com/public/?q=ulink&fn=Link&ssid=8886&id=23pyohswq90ngtca9rlr96mm5g17f&id2=7kv8iqkhjl7s2oa7c7pb4vsmlqi10
> ), a division of Clinsys Clinical Research, Inc., partners with clients globally to provide customized Phase I-IV clinical trial alternative solutions to the conventional outsourcing model. For more information, visit clinsys.com <
http://app.bronto.com/public/?q=ulink&fn=Link&ssid=8886&id=23pyohswq90ngtca9rlr96mm5g17f&id2=eg7fc8xgt72z2poxcewattidsdrj7
> .
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
